Japanese pharmaceutical company Kaken announced on December 26th that it has signed a license agreement with Johnson&Johnson for the global development, production, and commercialization of the STAT6 project that Kaken is currently developing. According to the terms of the agreement, Kaken will grant Johnson&Johnson an exclusive license for the global development, production, and commercialization of the STAT6 project, including KP-723 (an oral STAT6 inhibitor in preclinical development). Kaken will advance the completion of Phase I clinical trials for KP-723, after which Johnson&Johnson will conduct clinical development and commercialization worldwide. Kaken will retain its commercial rights in Japan, while Johnson&Johnson can choose to sign a joint promotion agreement with Kaken. Kaken will receive a $30 million advance payment from Johnson&Johnson. Based on development progress and sales milestones, Kaken will be eligible for successful payments of up to $1.2175 billion, as well as lower double-digit global sales royalties.